1. Home
  2. WKHS vs BYSI Comparison

WKHS vs BYSI Comparison

Compare WKHS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workhorse Group Inc.

WKHS

Workhorse Group Inc.

SELL

Current Price

$2.98

Market Cap

31.8M

ML Signal

SELL

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.62

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKHS
BYSI
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8M
31.4M
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
WKHS
BYSI
Price
$2.98
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.7K
★ 291.7K
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 86.92
N/A
EPS
N/A
★ N/A
Revenue
★ $763,173.00
N/A
Revenue This Year
$61.80
N/A
Revenue Next Year
$67.74
$49.96
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.53
$0.57
52 Week High
$11.80
$2.44

Technical Indicators

Market Signals
Indicator
WKHS
BYSI
Relative Strength Index (RSI) 47.37 40.48
Support Level $2.81 $0.60
Resistance Level $3.56 $0.80
Average True Range (ATR) 0.11 0.12
MACD 0.01 -0.02
Stochastic Oscillator 46.56 7.40

Price Performance

Historical Comparison
WKHS
BYSI

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: